Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05243290 · ClinicalTrials.gov registry record · NA

Nicotinamide Riboside Clinical Trial for GWI

A NA study of Gulf War Illness, sponsored by Roskamp Institute.

Recruiting
Registry status
NA
Development phase
52
Enrollment target
2
Study locations

NCT05243290 is a NA study of Gulf War Illness that is actively recruiting participants, run by Roskamp Institute. The registered enrollment target is 52 participants, below the 126-participant average among 14 other Gulf War Illness trials with a reported enrollment target (59% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05243290, a NA study of Gulf War Illness, is actively recruiting participants, sponsored by Roskamp Institute.

RECRUITING
Registry status
NA
Development phase
52 participants
Enrollment target
2
Study locations

Study Summary

In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Nicotinamide Riboside

Study Locations (2)

Florida

  • Nova Southeastern University - Fort Lauderdale
  • The Roskamp Institute - Sarasota

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2022-04-13
Est. Completion 2025-12-31
Phase NA

Sponsor

Roskamp Institute

7 total trials

What the Registry Record Tells You About NCT05243290

The ClinicalTrials.gov registry entry for NCT05243290 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 14 other Gulf War Illness trials with a reported enrollment target (59% lower). The listed sponsor is Roskamp Institute, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gulf War Illness appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05243290 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05243290 about?

NCT05243290 is a clinical study titled "Nicotinamide Riboside Clinical Trial for GWI". In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).

What is the current status of trial NCT05243290?

This trial is currently recruiting. It is a NA study. The enrollment target is 52 participants. The study started on 2022-04-13. Estimated completion is 2025-12-31.

What conditions does trial NCT05243290 study?

This clinical trial studies the following conditions: Gulf War Illness.

What interventions are being tested in trial NCT05243290?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Nicotinamide Riboside (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05243290?

This trial is sponsored by Roskamp Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05243290 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gulf War Illness

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.